In a groundbreaking advancement poised to reshape the landscape of multiple myeloma treatment, researchers from the Icahn School of Medicine at Mount Sinai, Bristol Myers Squibb, and the University of Oxford have unveiled a novel method to rejuvenate exhausted immune cells, particularly T cells, which are critical in the fight against cancer. Published in the prestigious journal Blood, their paired studies illuminate the potential of mezigdomide—an innovative cereblon E3 ligase modulator developed by Bristol Myers Squibb—to restore the vitality and function of T cells debilitated by chronic cancer exposure, significantly enhancing the therapeutic efficacy of existing immunotherapies.
Multiple myeloma, a malignancy of plasma cells residing in the bone marrow, has seen transformative improvements in patient outcomes due to the advent of T cell-based therapies, namely CAR-T cells and bispecific antibodies. However, a persistent clinical challenge remains: the eventual relapse of many patients. This relapse is often attributed to a phenomenon known as T cell exhaustion, where T cells progressively lose the capacity to effectively recognize and eradicate cancer cells. This functional decline severely limits the durability and depth of responses to immunotherapies, posing a formidable barrier to curative treatments.
The research spearheaded by Dr. Samir Parekh elucidates how mezigdomide directly counters this exhaustion. By targeting notoriously dysfunctional T cell populations expressing inhibitory receptors like PD-1 and TIGIT, the drug fosters a cellular environment where these impaired immune cells are reactivated. Experimental data obtained from bone marrow samples of patients with relapsed multiple myeloma showcased a marked reduction in exhaustion markers following mezigdomide treatment. Concurrently, the capacity of engineered CAR-T cells and bispecific T cell engagers to clear tumor cells was significantly amplified in preclinical models, suggesting a robust synergistic effect capable of achieving deeper tumor remission and prolonged survival.
At the heart of this mechanism lies the targeted degradation of two critical transcription factors: IKZF1 (Ikaros) and IKZF3 (Aiolos). These proteins serve as key regulatory nodes sustaining the gene expression and epigenetic landscapes that enforce T cell dysfunction. Utilizing cutting-edge multi-omic strategies encompassing gene expression profiling and three-dimensional genome architecture mapping, the team unveiled how these factors intricately preserve the exhausted state. Removal of Ikaros and Aiolos effectively rewired genetic circuits, reprogramming T cells from a quiescent, incompetent state into highly active, tumor-attacking effectors.
Lucia Chen, the study’s first author, emphasized the novelty of shifting investigative focus from the myeloma cells themselves to the surrounding tumor microenvironment—particularly immune cells. Her insights reveal that mezigdomide liberates immune cells from epigenetic restraints imposed by Ikaros and Aiolos, thereby invigorating the anti-tumor immune response. This discovery not only opens avenues for improving multiple myeloma therapies but also broadens the horizon for similar approaches against other malignancies characterized by T cell dysfunction.
Dr. Parekh further highlighted the transformational nature of mezigdomide’s mode of action. By dismantling Ikaros and Aiolos, mezigdomide induces a profound epigenetic shift, allowing T cells to regain production of vital cytokines and chemokines essential for orchestrating a vigorous immune attack. This molecular reset is more than a temporary boost—it represents a fundamental correction of the immune system’s capacity to sustain long-lasting anti-cancer activity, addressing a core obstacle faced by patients with heavily pretreated, relapsed disease.
The confluence of these findings underscores a compelling rationale to integrate mezigdomide with established T cell-based immunotherapies in clinical trials. Indeed, several early-phase studies are underway, exploring the simultaneous administration of mezigdomide to potentiate therapies like CAR-T and bispecific antibodies. These trials could herald a new era in which the synergistic targeting of both cancer cells and the immune microenvironment transforms outcomes for previously refractory multiple myeloma cases.
Anita Gandhi of Bristol Myers Squibb underscored the strategic importance of combining tumor-intrinsic and extrinsic therapeutic approaches. While notable advances have emerged in myeloma treatment, the persistence of unmet needs highlights the critical role of academic-industry collaboration in moving forward. She noted that innovations such as targeted protein degradation—exemplified by mezigdomide—may provide the scientific foundation essential for the next generation of cancer therapeutics tailored to overcome immunological barriers.
For patients confronting relapsed multiple myeloma, many of whom endure immunosuppression from prior therapies, this breakthrough holds particular promise. Dr. Parekh remarked that rekindling T cell functionality through molecular degradation of exhaustion regulators could substantially enhance the efficacy and longevity of disease control. This could translate into deeper, more durable remissions and improved survival outcomes, effectively rewriting the prognosis for thousands affected by this challenging cancer.
The collaborative nature of this research—joining expertise from Mount Sinai, Bristol Myers Squibb, the University of Oxford, and the University of Navarra in Spain—combined with diverse funding sources including the International Myeloma Society and the National Cancer Institute, epitomizes a model of translational science accelerating from bench to bedside. With comprehensive molecular insights now available, the field is poised to exploit epigenetic modulation as a therapeutic avenue in immune-oncology.
As the scientific community eagerly awaits the results of ongoing clinical trials, the dual publication in Blood cements the importance of understanding how reprogramming immune cells can invigorate existing cancer therapies. The innovative approach of harnessing cereblon modulators to degrade transcriptional gatekeepers underscores a paradigm shift in immunotherapy—one that places immune plasticity and resilience at the forefront of next-generation cancer treatment.
In sum, mezigdomide represents not only a promising enhancement for multiple myeloma immunotherapies but also a beacon illuminating untapped epigenetic mechanisms driving T cell exhaustion. Its potential to rewrite immune cell fate paves the way for durable, effective treatments that could redefine survivorship for patients burdened by intractable cancers. The future of immune reactivation in oncology has decidedly entered a new era, with epigenetic targeting as a cornerstone strategy.
Subject of Research: Cells
Article Title: Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies
News Publication Date: May 18, 2026
Web References:
https://doi.org/10.1182/blood.2025030891
https://doi.org/10.1182/blood.2025030873
Keywords: Multiple myeloma, Immunotherapy, T cell exhaustion, Mezigdomide, Cereblon E3 ligase modulator, IKZF1 (Ikaros), IKZF3 (Aiolos), CAR-T cells, Bispecific antibodies, Epigenetic reprogramming, Targeted protein degradation, Cancer immunology
Tags: advances in cancer immunotherapy researchbispecific antibody treatment for myelomaenhancing CAR-T cell therapy efficacyimmune cell modulation in myelomaimproving durability of cancer immunotherapiesmezigdomide cereblon E3 ligase modulatormultiple myeloma relapse mechanismsnovel immunotherapy strategies for cancerovercoming immunotherapy resistancerestoring T cell function in cancerT cell exhaustion in multiple myelomaT cell rejuvenation in hematologic malignancies
